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Abstract
Background: Trastuzumab, a humanized monoclonal antibody against the HER2 receptor is
currently being used in breast and other tumor types. Early studies have shown that a variable
proportion of cervical carcinoma tumors overexpress the HER2 receptor as evaluated by diverse
techniques and antibodies. Currently it is known that a tumor response to trastuzumab strongly
correlates with the level of HER2 expression evaluated by the Hercep Test, thus, it seems desirable
to evaluate the status of expression of this receptor using the FDA-approved Hercep Test and
grading system to gain insight in the feasibility of using trastuzumab in cervical cancer patients.
Methods: We analyzed a series of cervical cancer cell lines, the primary tumors of 35 cases of
cervical cancer patients and four recurrent cases, with the Hercep Test in order to establish
whether this tumor type overexpress HER2 at level of 2+/3+ as trastuzumab is currently approved
for breast cancer having such level of expression.
Results: The results indicate that only 1 out of 35 primary tumors cases overexpress the receptor
at this level, however, two out of four recurrent tumors that tested negative at diagnosis shifted
to Hercep Test 2+ and 3+ respectively.
Conclusions: The low frequency of expression in primary cases suggests that trastuzumab could
have a limited value for the primary management of cervical cancer patients, however, the finding
of "conversion" to Hercep Test 2+ and 3+ of recurrent tumors indicates the need to further
evaluate the expression of HER2 in the metastatic and recurrent cases.
Background
Cervical carcinoma is a leading cause of death in women
of reproductive age worldwide, particularly in developing
countries. While curable in early stages, the treatment
results of locally advanced disease are unsatisfactory. The
current standard of treatment -cisplatin-based chemoradi-
ation- fails to cure at least 15% to 45% of bulky IB to IIIB
patients, and in addition, multimodality treatment
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incorporating chemotherapy, surgery and radiation at its
best is unlikely to substantially increase the cure rate.
Because of this, the logical step to follow is the testing of
molecular targeted therapies trying to improve the prog-
nosis of cervical cancer patients [1].
Human papillomavirus infection is recognized as the
stronger etiological factor for the development of this
tumor; however, overexpression of the epidermal growth
factor receptor family members is also common and
seems to play an important oncogenic role [2]. HER2
(also known as c-erbB-2) is a transmembrane receptor
protein with tyrosine kinase activity that belongs to this
family and it is overexpressed in a number of solid
tumors. Its overexpression and prognostic significance in
breast cancer led to the development and approval of the
use of trastuzumab (Trastuzumab, Genentech, South San
Francisco, CA), a recombinant monoclonal antibody to
HER2, for the treatment of patients with metastatic breast
carcinomas overexpressing HER2 [3].
Until more recently, poor standardization in HER2 status
evaluation precluded reliable comparison of overexpres-
sion rates in different tumors. A source of variability in
results not only comes from methodological variations in
tissue processing (time to fixation, duration of fixation,
denaturation, heating, antigen retrieval, the staining pro-
cedure) and grading scores but also from the antibody
used. This issue was addressed by Press et al., who showed
extremely variable results in 187 breast cancer specimens
evaluated with 7 polyclonal and 21 monoclonal antibod-
ies [4]. However, standardized methodologies have been
introduced recently for these analyses, and have identified
frequencies of 51%, 44%, 26% and 25% in Wilm's tumor,
bladder, pancreatic and breast carcinoma, respectively.
Other tumors tested had frequencies below 20% [5].
Before the introduction of the Hercep Test, it was known
that a variable subset of cervical carcinomas ranging from
8% to 77% express HER2 as evaluated by diverse methods
[6-14] and that in some studies its overexpression has
shown to confer a worse prognosis [7-9,13]. Because these
results on HER2 expression in cervical cancer were
obtained before the standardization required in breast
cancer, we wanted to investigate the expression status of
HER2 using the Hercep Test in a series of cervical carci-
noma cell lines, primary tumors of locally advanced cervi-




Thirty-five paraffin-embedded tumor tissues from
patients FIGO staged as IB2 to IIIB, treated with standard
radiation concurrent with weekly cisplatin. Diagnosis was
made on the basis of routine hematoxilin-eosin examina-
tion under light microscopy according to the World
Health Organization criteria. Tumor specimens at diagno-
sis were taken before any treatment was instituted whereas
the tumors samples from the four recurrent cases were
also taken before patients received any second line
therapy.
Cell lines and reagents
DMEM culture media and Fetal Calf Serum were pur-
chased from Gibco BRL Life Technologies (Grand Island,
New York). HeLa, CasKi, SiHa and C33A carcinoma cell
lines were obtained from the ATCC. The cell line ViBo
established from a Mexican patient with cervical cancer
was kindly provided by Dr. Monroy (FES Zaragoza,
UNAM, Mexico City). Cells were grown in DMEM supple-
mented with 10% FCS at 37°C and 5% CO2. Cell lines
were grown on two-chamber polysterene vessel Falcon®
(Becton Dickinson, NJ.) and subsequently formalin-fixed
for 24 hrs at room temperature, then rehydrated in graded
ethanol. Afterwards immunochemistry was performed as
below described.
Hercep test
Hercep Test was performed following the manufacturer's
guidelines of HER2 protein expression as follows. Sec-
tions were deparaffinized in xylene and rehydrated
through graded ethanols to distilled water. The sections
were immersed in Dako Epitope Retrieval Solution (10
mM citrate buffer, pH6) that had been preheated to 95°C
in a water bath and then heat-treated at 95°C for 40 min.
After a 20-minute cooldown period at room temperature,
the sections were washed with Dako Wash Buffer, a proce-
dure that followed every subsequent incubation. Endog-
enous peroxidase was blocked with Dako Blocking Buffer
(0.3% hydrogen peroxide containing 15 mM sodium
azide) for 5 min at room temperature. The sections were
incubated with the primary polyclonal antibody, an affin-
ity-purified rabbit antihuman HER2 antibody supplied in
the kit, for 30 min at room temperature. Bound primary
antibody was labeled by incubating the slides with the
Dako Visualization reagent (horseradish peroxidase-
labeled dextran polymer conjugated to affinity-purified
goat antirabbit immunoglobulins in Tris-HCl) for 30 min.
Color development was achieved with 3,3'-diaminoben-
zidine (DAB) for 10 min. The sections were counter-
stained with hematoxylin and eosin. To confirm
validation of the staining run, control cell slides, which
were provided in the kit and consisted of three pelleted,
formalin-fixed, paraffin-embedded human breast cell
lines with known HER2 positivity (MDA-231: 0; MDA-
175: 1+; SK-BR-3: 3+), were also stained simultaneously.
In the negative controls, the primary antibody was
replaced by normal rabbit serum (Dako Negative Control
Reagent) for the HER2 primary antibody. The antibodyBMC Cancer 2004, 4:59 http://www.biomedcentral.com/1471-2407/4/59
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used in Hercep Test did not exhibit cross-reactivity to
HER3 and HER4 in western blot analysis.
Following the FDA scoring guidelines for breast carcino-
mas, only membrane staining intensity and pattern were
evaluated using the 0–3+ scale as illustrated in the Hercep
Test kit scoring guidelines (0 for no staining at all or mem-
brane staining in less than 10% of the tumor cells; 1+ for
only partial, weak staining of the cell membrane of more
than 10% of the tumor cells; 2+ for moderate staining of
the complete cell membrane in more than 10% of the
tumor cells; 3+ for intense staining of the complete mem-
brane in more than 10% of the tumor cells). The analysis
was performed by a pathologist (VP-S) familiarized in the
use of Hercep Test for breast cancer patients. In accord-
ance with the Hercep Test kit guide, HER2 overexpression
was assessed as negative for scores of 0 or 1+ and positive
for scores of 2+ and 3+.
FISH in the four recurrent cases
Amplification of Her-2/neu was evaluated using the Path-
Vysion DNA Probe Kit (Vysis), which uses a dual-color
probe for determining the number of copies of both Her-
2/neu  (orange) and the chromosome 17 centromeres
(green). The kit was used following the manufacturer's
instructions with a few minor modifications. Slides con-
taining 5µ thick paraffin-embedded tissue sections of
studied cervical tumor cases and a known Her-2/neu
amplified breast tumor were placed on a slide warmer
overnight at 58°C, followed by deparaffinization in Xilol,
dehydration in 100 ethanol, and drying on a slide warmer
at 45 to 50°C. Slides were then pretreated with 0.2 N
hydrochloric acid for 20 minutes, followed by washes in
purified water and immersion in Vysis wash buffer. They
were subsequently immersed in Vysis protease solution at
37°C for 10 minutes, washed in Vysis wash buffer, and
dried on the slide warmer. The slides were then immersed
in 10% buffered formalin at room temperature for 10
minutes, immersed in Vysis wash buffer, and dried on the
slide warmer. Sections were denatured by placing the
slides in formamide for 5 minutes at 72°C followed by
dehydration in 70, 85 and then 100% ethanol. Slides were
then dried on a slide warmer, and 10 µl of probe was
applied. They were then coverslipped, sealed and placed
in a prewarmed humid incubation chamber at 37°C for
21 hours. This was followed by immersion in prewarmed
postwash solution at 72°C for 2 minutes. The slides were
air-dried, and a 4',6-diamidino-2-phenylindole (DAPI)
counterstain was applied.
The scoring system used is described in detail in the man-
ufacturer's instruction. A minimum of 60 nuclei were
scored by each of 2 observers using a Zeiss Axioskop-2 flu-
orescent microscope with V.2 filter. The ratio of Her-2/neu
signals (orange) to chromosome 17 centromere signals
(green) was determined with ratios of <2.0 considered
nonamplified and those ≥ 2.0 amplified.
Results
The immunohistochemical expression of HER2 in the pri-
mary tumors of 35 patients at diagnosis was evaluated.
Accordingly, these patients had no received any previous
anticancer therapy; their mean age was 40.8 years; 5 were
staged as IB2-IIA, 14 as IIB and 16 as IIIB; 31 and 4 were
histologically classified as squamous and adeno/adenosq-
uamous respectively. Overexpression of HER2 was dem-
onstrated in only one out of 35 cases, which had a score
of 3+ (not shown). The remaining cases were interpreted
as negative [score of 0]. The case with HER2 overexpres-
sion at diagnosis was a 56-year old woman diagnosed
with a FIGO stage IIB large cell poorly differentiated squa-
mous cell carcinoma, who received treatment with 6
weekly courses of cisplatin concurrent with external beam
radiation and brachytherapy. She is currently free of dis-
ease at 44 months of follow-up. At a median follow-up
time 40 months, seven patients have relapsed.
HER2 expression at recurrence could only be analyzed in
four of these seven relapsed patients in whom whose
recurrent disease was histopathologically confirmed. Two
of these four tested positive with a staining intensity of 2+
and 3+ respectively, (Figures 1 and 2), both cases were
squamous cell carcinomas and tested negative in the pre-
treatment surgical specimen
The five cervical cancer cell lines were negative.
None of the four recurrent cases tested by FISH were HER2
amplified (Figure 3).
Photomicrography of a recurrent tumor positive at a inten- sity of 2+ Figure 1
Photomicrography of a recurrent tumor positive at a inten-
sity of 2+. (200X).BMC Cancer 2004, 4:59 http://www.biomedcentral.com/1471-2407/4/59
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Discussion
Molecular targeted therapies are currently being tested in
a variety of tumor types with promising results. Because
HER2 overexpression occurs and is related to a worse
prognosis in cervical cancer, [7-9,13], its blockade with
trastuzumab could potentially have therapeutic value.
This monoclonal antibody is currently widely used in
metastatic breast cancer and is being evaluated in an adju-
vant setting as well as in a variety of tumor types [3,15-
17], Based on the fact that the efficacy of this antibody is
strongly associated to the level of HER2 expression in the
primary tumor, the FDA approved the Hercep Test in the
aim to grade the expression level so that only those
patients whose tumors exhibit a 2+/3+ levels are candi-
dates to trastuzumab therapy, though currently in most
centers, tumors expression of 2+ is considered undetermi-
nate therefore these cases are also evaluated by FISH anal-
ysis [18].
Previous reports on cervical cancer using non-standard-
ized methods for HER2 expression showed that up to 77%
of cases express the receptor and that in general HER2
expression predominates in adenocarcinoma and adenos-
quamous carcinoma histologies [6-14] In this work, using
the Hercep Test with its corresponding guidelines for eval-
uation, we found contrastating results as none of the cell
lines expressed HER2 and only a single tumor of squa-
mous histology (1 out of 35) expresses this oncoprotein at
a level of 3+. Such a discrepancy does not seem to be lim-
ited to this tumor type. For instances, in ovarian clear cell
carcinoma a 43% of overexpression was reported utilizing
systems other than Hercep Test [19], however, when eval-
uated with this standardized test, only 1 out of 17 tumors
expressed 3+ [20]. Likewise, the proportion of patients
with 2+/3+ expression level of HER2 with the Hercep Test
is uniformly low in tumor such as lung [21], colorectal
carcinomas [22], gallbladder [23], and melanoma [24]. A
variety of factors such as the kind of antibody used, the
technique per se, and scoring criteria may explain such
phenomenon and its clarification requires further studies.
A recent paper by Bellone et al., have reported that a sub-
stantially higher proportion of cervical cancer cells lines
either established from fresh tumors or commercial ones
(including CasKi, SiHa, HeLa and C33A which are nega-
tive by immunochemistry) express the receptor when
evaluated by flow-cytometry and are growth inhibited
when incubated with trastuzumab or trastuzumab plus IL-
2 [25]. These data led them to suggest the targeting the
HER in cervical cancer could be more effective than the
indicated by low immunohistochemical expression [25].
However, it is largely known that in breast [26] and more
recently in lung cancer [27], tumor responses are almost
confined to those with a 3+ level of expression. For
instances, in a recent published study in 111 assessable
breast cancer patients, the response rate to single agent
trastuzumab for those expressing 3+ versus 2+ was 35%
and 0% respectively [26], while in lung cancer, a phase II
trial of gemcitabine-cisplatin with or without trastuzumab
in HER2-positive patients, yet there was not overall differ-
ences in response between both arms, the benefit was lim-
ited to those with 3+ of expression with the Hercep Test.
Accordingly, five out of six patients with such level of
expression receiving trastuzumab plus gemcitabine-cispl-
atin showed response [27]. These data argue against the
potential usefulness of trastuzumab in cervical cancer
patients with HER expression that can only be detected by
flow cytometry [25].
On the other hand, the HER2 expression in breast cancer
is relatively stable, with 95% concordance between the
HER2 status of primary and metastatic lesions, being rare
a shift from positivity in the primary to negativity in the
metastases [5]. Conversely, 6% of breast cancer patients
whose primary tumors are HER2 negative, convert to high
expression (Hercep Test 3+) in their metastases [28]. Such
behavior is in line with experimental observations that
receptor activation potentiates tumor cell motility, pro-
tease secretion and invasion, and also modulates cell cycle
checkpoint function, DNA repair, apoptotic responses
and multidrug resistance [29,30]. The findings of "conver-
sion to positive" in cells of recurrent cervical tumors
showed by us and other authors [25,31] strongly suggest
that expression of HER2 may have a role in tumor
Photomicrography of a recurrent tumor positive at a inten- sity of 3+ Figure 2
Photomicrography of a recurrent tumor positive at a inten-
sity of 3+. (200X).BMC Cancer 2004, 4:59 http://www.biomedcentral.com/1471-2407/4/59
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resistance and progression as shown in experimental
models, and therefore its targeting in recurrent cervical
cancer could have therapeutic value.
It is remarkable the finding that none of the four recurrent
cases, including the two that converted to IHC positive
analyzed by FISH showed HER2 gene amplification. This
result is unlikely to be a false negative as the green signal
was perfectly observed in most of the cells. Previous stud-
ies in cervical cancer have shown that the frequency of
gene amplification as determined by FISH is low irrespec-
tive of tumor histology. Mark et al., reported only 2 out of
23 cases amplified using the Her-2/neu FISH probe (Vysis,
Inc., Downers Grove, IL) both of which were adenocarci-
nomas [32]. In a more recent study looking at DNA copy
number of cervical adenocarcinomas, it was found that
despite more than 50% of patients had chromosome 17q
copy number gains, only 9% (2 out of 22) of these tumors
showed an HER-2/neu protein over-expression at the level
of 2+ with the Hercep test. These findings suggest that
amplification of HER-2/neu is rare in cervical adenocarci-
nomas and that low level chromosome 17q copy number
gains are not associated with HER-2/neu overexpression
[33]. Such overexpression without gene amplification
could result from transcriptional deregulation leading to
increased receptor expression [34] and is not a rare phe-
nomenon in breast carcinoma [35].
Conclusions
In conclusion, our study suggest that the clinical useful-
ness of anti-HER2 antibodies in the primary treatment of
cervical cancer patients may be limited due to the low
frequency of HER overexpression, nevertheless, it is desir-
able to further test a larger number of recurrent cervical
cancer patients by IHC and FISH analyses regardless of the
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Photomicrography of the FISH analysis of a negative case of a recurrent tumor that was Hercep Test-positive, and a control  positive case of breast carcinoma Figure 3
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